癌症活檢市場 - COVID-19 的增長、趨勢、影響和預測(2021-2026)
Cancer Biopsies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
在預測期內，癌症活檢市場預計將以 6.5% 的複合年增長率增長。
COVID 19 對醫療行業產生了重大影響，尤其是癌症活檢市場。在這種大流行中，政府採取的社會疏遠措施大大減少了獲得醫療保健服務和就診的機會，只允許在緊急情況下接受患者。除此之外，據自然癌症雜誌報導，2020 年，美國醫療保險和醫療補助服務中心將篩查列為此次大流行期間的低優先級服務。此後，蘇格蘭和愛爾蘭等其他國家也在 COVID 19 期間暫停了其癌症篩查計劃。
癌症疾病的增加對癌症活檢市場的增長也起著重要作用。根據國際癌症研究機構 (IARC) 的數據，到 2040 年，全球新癌症病例將達到 2750 萬，到 2040 年癌症死亡人數將增加到 1630 萬。根據美國國家癌症研究所 (NCI) 的數據，到 2021 年，美國將有 284,200 例乳腺癌病例、149,500 例結直腸癌病例和 83,730 例新膀胱癌病例。這表明癌症活檢市場在未來幾年可能會上升。
市場主要參與者的技術進步和產品發佈也促進了市場的增長。例如，2020年2月，Qiagen推出了Liquid Biopsy PIK3CA試劑盒，以改善乳腺癌的精準醫療。 PIK3CA 基因產生的蛋白質 p110ALPHA 參與細胞生長和分裂，導致該基因發生突變，導致細胞生長和分裂不受控制，從而導致癌症。這種特殊的活檢 PIK3CA 試劑盒有助於指導乳腺癌患者的治療決策。因此，預計這將導致未來市場的顯著增長。本報告調查了癌症活檢市場，並按產品、類型、應用、最終用戶、地區和進入市場的公司概況介紹了市場概況以及趨勢。
The Cancer Biopsies Market is expected to grow with an estimated CAGR of 6.5%, over the forecast period.
COVID 19 has a great impact on the medical industry, especially on the cancer biopsies market. In this pandemic due to social distancing measures imposed by the governments, the use of healthcare services and visits to the hospital have drastically reduced, due to which the patients were only allowed /permitted in the case of an emergency. In addition to this according to the Nature Cancer journal, in 2020, the Centers for Medicare and Medicaid Services in the United States have classified screening as a low-priority service during this pandemic. Following this, other countries such as Scotland, Ireland had also suspended the cancer screening programs during COVID 19.
The rise in cancer diseases is also playing a key role in the cancer biopsies market's growth. In 2018, according to International Agency for Research on Cancer (IARC), new cancer cases are expected to grow to 27.5 million and 16.3 million cancer deaths, globally, by 2040. In 2021, according to the National Cancer Institute (NCI) the estimated number of new bladder cancer cases were 83,730 whereas breast cancer cases were 284,200, colon and rectal cancer accounting to149,500 in United States. This indicates a potential elevation of cancer biopsies market in coming years.
The technological advancements and product launches by some of the key players of the market are also attributed to the markets growth. For instance, in Feb 2020, to improve the precision medicine in breast cancer, Qiagen has launched Liquid Biopsy PIK3CA kit. Protein p110α which is made by PIK3CA gene, involved in growth and division of cell, mutation in this gene causes uncontrollable cell growth and division, that leads to cancer. This particular biopsy PIK3CA kit will help in guiding treatment decisions for the breast cancer patients. Hence, owing to above mentioned factors, the market is expected to witness significant growth in the future.
The breast cancer segment is expected to have a positive growth over the forecast period. The rising burden of breast cancer is a key factor driving the market. The World Health Organization stated that in 2020, women diagnosed with breast cancer were 2.3 million, and 685 000 deaths were reported globally. Women who were diagnosed with breast cancer in the past 5 years and are alive were 7.8 million globally.
In addition, a study was initiated in 2019 named 'MRI-targeted Biopsy of the Prostate' to evaluate the clinical significance of prostate cancer detection with MRI targeted biopsy. It is being studied specifically in prostate cancer and prostate neoplasm. Also, a study titled 'Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer' which was initiated in 2018 was studying the role of Ultrasound-guided axillary lymph nodes FNAC and\or CNB in breast cancer. The above conditions show that the incidence of breast cancer disease and technological advancements in the cancer biopsies market in the breast cancer application segment is expected to have a promising growth rate for the forecast period.
North America holds the major market share in the Cancer Biopsies market. The rising incidence of cancer diseases, the rising elderly population, technological advancements are key factors attributed to the growth rate of the cancer biopsies market. National Cancer Institute estimated that 43% of all cancers diagnosed in men are lung, colorectal, and prostate cancers and the most common cancers in women are breast, lung, and colorectal which accounts for 50% of new cancers diagnosed in 2020 in the United States.
Foundation Medicine, Inc, an United States company based in Cambridge, Massachusetts which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for hematologic malignancies, solid tumors, and sarcomas, announced that the Food and Drug Administration (FDA) approved its FoundationOne CDx, in 2020, which is considered the first FDA-approved tissue-based broad companion diagnostic (CDx) that is validated for all solid tumors both clinically and analytically.
According to the American Cancer Society in 2020, 1,806,590 new cancer cases and 606,520 cancer deaths were estimated in the United States. With rising awareness on preventive care and early diagnosis especially with the technological development of liquid biopsies in recent time, the rate of cancer survivors has increased potentially. According to National Cancer Institute, it is estimated the cancer survivors were projected to increase to 22.2 million by 2030 from 16.9 million in 2019. Hence, considering above mentioned factors, the market is expected to witness significant growth in the future.
The Cancer Biopsies market is moderately competitive with several players across the globe. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of cancer diseases, especially the recent developments in liquid biopsies, many regional players are expected to be part of the cancer biopsies market over the forecast period. Some of the major players of the market are QIAGEN N.V, Illumina, Inc., Becton, Dickinson and Company, Myriad Genetics, Thermo Fisher Scientific, Inc., etc